The End or a New Era of Development of SARS-CoV-2 Virus: Genetic Variants Responsible for Severe COVID-19 and Clinical Efficacy of the Most Commonly Used Vaccines in Clinical Practice

• Published in: Vaccines Vol. 11; no. 7; p. 1181
• Main Authors: Miteva, Dimitrina, Kitanova, Meglena, Batselova, Hristiana, Lazova, Snezhina, Chervenkov, Lyubomir, Peshevska-Sekulovska, Monika, Sekulovski, Metodija, Gulinac, Milena, Vasilev, Georgi V., Tomov, Luchesar, Velikova, Tsvetelina
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 30.06.2023; MDPI
• Subjects: Clinical trials; Coronaviruses; COVID-19; COVID-19 vaccines; Disease prevention; Disease transmission; Effectiveness; efficacy; Enzymes; Genetic diversity; Genetic variance; Genomes; Global health; Immune system; Infections; Medical research; Medicine; Mortality; mRNA vaccines; Mutation; Pandemics; Proteins; Public health; R; Review; safety; SARS-CoV-2 variants; Severe acute respiratory syndrome coronavirus 2; Vaccines; Viral diseases; Viruses; Bulgaria; United Kingdom > UK; Brazil; COVID-19; effectiveness; SARS-CoV-2 variants; vaccines; safety; efficacy

Although the chief of the World Health Organization (WHO) has declared the end of the coronavirus disease 2019 (COVID-19) as a global health emergency, the disease is still a global threat. To be able to manage such pandemics in the future, it is necessary to develop proper strategies and opportunit...